About us

Belgium-based biotech company

Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology

Hearing Loss

Based on a unique mechanism of action (restoration of synapses’ coupling) and after generating encouraging pre-clinical results in several animal models, Dendrogenix primary asset DX243 is expected to start regulatory toxicology studies and phase 1 clinical trials in 2022 in hearing loss.

DX243 studies

DX243 efficacy was pre-clinically demonstrated in various species and models in prevention and/or treatment of hearing loss with different ways of administration. These studies were performed in several academic institutions such as the Karolinska Institute (Sweden), the University of Tubingen (Germany), the CSIC (Spain) and the University of Liège (Belgium).

Neurology

Dendrogenins appear to own beneficial neuronal properties (i.e. excitotoxicity, inflammation, neuritogenesis, energetic metabolism, synapses) associated with the regeneration of the nervous system. Since these properties are associated with many neurological diseases, the company also intends to further advance its pre-clinical pipeline of products in the neurology area.

2000
Dendrogenix is founded
0
Team members
0
Partners
4500
Cups of Coffee

Dendrogenins

The origin of the discovery of our Dendrogenins results from the study of tamoxifen's mode of action through functional genomics studies. Tamoxifen has been the first drug used to treat hormone-dependent breast cancer. During metabolic and functional genomics studies associated with the activity of this drug, an ancillary pathway for Tamoxifen which is involved in the control of cell differentiation has been identified by Dr. Marc Poirot and his scientific team at the INSERM Institute in Toulouse. This pathway is based on serial sterol metabolism that generates molecules with original structures called Dendrogenins. These molecules stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors.

Our Team

We stay on top of our industry by being experts.

Stéphane SILVENTE

Stéphane SILVENTE

Chief Executive Officer
Entrepreneur with 30+ years’ experience in building and managing dynamic teams.
Frederic THIVET

Frederic THIVET

CHief financial officer
As an experienced lawyer and senior manager Frederic developed skills in legal, finance, administration and HR.
Pierre ATTALI, MD

Pierre ATTALI, MD

Chief Medical Officer
Dr. Pierre Attali has over 30 years’ experience in global R&D in the life sciences industry.
Philippe LEFEBVRE, MD, PhD

Philippe LEFEBVRE, MD, PhD

Chief Scientific Officer
Prof. Lefebvre is doctor of biomedical science, otolaryngology specialist and completed a postdoctoral fellowship.
Nicolas CARON

Nicolas CARON

Head of Preclinical Development
Nicolas started his career in the biotech industry with Affichem where he managed several preclinical projects.
Arnaud RIVES, PhD

Arnaud RIVES, PhD

Head of Chemistry
Arnaud has 10 years’ experience in multi-step synthesis and implementation of optimization processes.
Gary SCHONBERG

Gary SCHONBERG

Chief Business Development Officer
Gary was involved or led many licensing, fundraising, equity capital markets and M&A deals in the life sciences industry.
Quentin MARLIER, PhD

Quentin MARLIER, PhD

Biology Project manager
Quentin completed his thesis at the GIGA on cell cycle dysregulation in central nervous system pathologies.

Board of Directors

Emile LORIA (MD)

Chairman of the Board
Dr. Loria was a researcher in the cancer institute in Villejuif and after in the cancer and immunogenetics institute (INSERM-CNRS).

Gerard TOBELEM (MD)

Board member
Dr. Tobelem was hematology professor at Paris 7 University and former head of Paris’ Lariboisière hospital blood disorders’ department.

Philippe LEFEBVRE (MD, PhD)

Board Member
Prof. Lefebvre is doctor of biomedical science, otolaryngology specialist and completed a postdoctoral fellowship.

Stéphane SILVENTE

Board member
Entrepreneur with 30+ years’ experience in building and managing dynamic teams.

Hugues WALLEMACQ (PhD)

Board member
Graduating as doctor in veterinary medicine from the University of Liège, Hugues pursued a PhD in immunology at the GIGA.

Partners

Contact

B34 +3 CHU de Liège

Avenue de l’Hôpital, 11
GIGA B34 +3
B4000 Liège
Belgium

Email: contact@dendrogenix.com